Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$6.69 USD
-0.08 (-1.18%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $6.68 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INO 6.69 -0.08(-1.18%)
Will INO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INO
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
INO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Other News for INO
INOVIO to Present at Upcoming Scientific Conference
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS) and Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals (INO) Receives a Buy from Oppenheimer
Inovio price target lowered by $7 at Oppenheimer, here's why
Commit To Purchase Inovio Pharmaceuticals At $7, Earn 34% Annualized Using Options